Latest stories on AGEN
Biggest stock movers Monday: XCNR, SGRY, AGEN
Seeking Alpha48 · neutralgeneral
Agenus reports response rate in colon cancer trial
Seeking Alpha64 · neutralproduct/pr
Agenus announces Phase 2 results from cohort of NEOASIS
The Fly58 · neutralproduct/pr
Agenus to Provide Third Quarter 2026 Financial Report and Development Update
StockTitan50 · neutralgeneral
Agenus to Participate in Chardan’s 10th Annual Healthcare Investor Conference
StockTitan52 · neutralproduct/pr
Agenus announces Armenia granted marketing authorizations for BOT+BAL
The Fly63 · neutralproduct/pr
Armenia Grants First Marketing Authorizations for Agenus’ BOT+BAL in Previously Treated MSS Metastatic Colorectal Cancer
StockTitan64 · neutralproduct/pr
Agenus highlights a three-year survival plateau for BOT+BAL in heavily pretreated recurrent ovarian cancer
MarketChameleon67 · bullishproduct/pr
Agenus announces 3-year follow-up results from Phase 1b C-800-01 trial
The Fly59 · neutralproduct/pr
Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026
StockTitan67 · bullishproduct/pr
Agenus to Present BOT+BAL Long-Term Survival Data and Translational Research With agenT-797 in Colorectal Cancer at SITC 2026
StockTitan56 · neutralproduct/pr
Agenus: Pivot To Neoadjuvant Setting In CRC Sends Stock Soaring - But Caution Advised
Seeking Alpha67 · bullishproduct/pr
Agenus: Hot Times As It Trudges Towards BOT/BAL Submission
Seeking Alpha58 · neutralproduct/pr
Rodman & Renshaw initiates Agenus stock with buy on cancer therapy
Investing.com Analyst Ratings61 · neutralanalyst
Agenus initiated with a Buy at Rodman & Renshaw
The Fly61 · neutralanalyst
Agenus initiated with a Buy at Chardan
The Fly61 · neutralanalyst
At a glance: stocks gapping down premarket
Seeking Alpha34 · bearishgeneral
Agenus files to sell 221,525 shares of common stock for holders
The Fly24 · bearishgeneral
Agenus Inc. (AGEN) Shareholder/Analyst Call - Slideshow
Seeking Alpha50 · neutralgeneral
Agenus Inc. (AGEN) Shareholder/Analyst Call Transcript
Seeking Alpha50 · neutralgeneral
Agenus to Present Three-Year Overall Survival Data for BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026
StockTitan63 · neutralproduct/pr
Agenus to Participate in Upcoming September Investor Conferences
StockTitan56 · neutralgeneral
Agenus: No colorectal cancer recurrences observed at updated follow-up in trial
The Fly73 · bullishproduct/pr